| Literature DB >> 32735224 |
Yang Xiang1, Hangyu Ji2, Yujia Zhou1, Fang Li1, Jingcheng Du1, Laila Rasmy1, Stephen Wu1, W Jim Zheng1, Hua Xu1, Degui Zhi1, Yaoyun Zhang1, Cui Tao1.
Abstract
BACKGROUND: Asthma exacerbation is an acute or subacute episode of progressive worsening of asthma symptoms and can have a significant impact on patients' quality of life. However, efficient methods that can help identify personalized risk factors and make early predictions are lacking.Entities:
Keywords: asthma; deep learning; electronic health records; health risk appraisal
Mesh:
Year: 2020 PMID: 32735224 PMCID: PMC7428917 DOI: 10.2196/16981
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Defined terms for asthma exacerbation prediction.
| Term | Definition |
| Index date | The date of the first diagnosis of asthma in a patient’s EHRa |
| Exacerbation date | The date of the first diagnosis of asthma exacerbation after the index date |
| Case group | Patients with asthma and later asthma exacerbations within 365 days and satisfying the inclusion and exclusion criteria |
| Control group | Patients with asthma but without exacerbations within 365 days and satisfying the inclusion and exclusion criteria |
| Prediction date | Training set: for the case group, the visit date before the exacerbation date; for the control group, the penultimate visit date within 365 days: Testing set A: the fifth visit starting from the index date Testing set B: defined analogously to the training set |
| Observed time window | The time window between the index date and the prediction date |
aEHR: electronic health record.
Figure 1The workflow of the prediction and risk analysis of asthma exacerbation.
Figure 2Cohort selection process for the study of asthma exacerbation. ED: emergency department; EHR: electronic health record; ICD: International Classification of Disease Code; OCS: oral corticoids.
Figure 3Overview of the time-sensitive attentive neural network model for asthma exacerbation prediction. ICD: International Classification of Disease Code; LSTM: long short-term memory.
The methods used for comparisons.
| Method | Note |
| LRa | A popular conventional machine learning algorithm [ |
| MLPb | The MLP model used in this study contains 1 input layer and 1 Softmax layer [ |
| LSTMc | The basic LSTM algorithm, taking the sequence of the clinical variables as input ordered by time. The variables in each visit are averaged |
| ALSTMd | Comprising 1 layer of LSTM and 1 layer of attention |
| TLSTMe [ | The time-aware LSTM model, which is one of the state-of-the-art predictive models. In TLSTM, the time gap is used to compute the information decay in the LSTM unit |
| RETAINf [ | A two-layer attention model, which is another state-of-the-art model for the prediction of disease onset. In RETAIN, the time features are not embedded as vectors but real values denoting the gaps from the first visit |
| ATTAINg [ | A modification of TLSTM with special types of attention mechanisms added (flexible attention). It also uses a similar time decay function as RETAIN. We implemented it ourselves using TensorFlow |
| TSANNh-I | The proposed TSANN model but with the second attention layer removed. Prediction is based on the final state of LSTM |
| TSANN-I-step | Apply the time-encoding method from Song et al [ |
| TSANN-II | A complete version of the proposed TSANN model |
aLR: logistic regression.
bMLP: multilayer perceptron.
eLSTM: long short-term memory.
dALSTM: attention long short-term memory.
eTLSTM: time-aware long short-term memory.
fRETAIN: Reverse Time Attention model.
gATTAIN: Attention-based Time-Aware Disease Progression.
hTSANN: time-sensitive attentive neural network.
Area under the curve (AUC) values by different models (–time: time information was excluded and +time: time information was included).
| Method | AUCa–time | AUC+time |
| LRb | 0.6447 | 0.6773 |
| MLPc | 0.6545 | 0.6753 |
| LSTMd | 0.6045 | 0.6567 |
| ALSTMe | 0.6346 | 0.6714 |
| TLSTMf | — | 0.6548 |
| ATTAINg | 0.6119 | 0.6597 |
| RETAINh | 0.6455 | 0.6882 |
| TSANNi-I | 0.6692 |
|
| TSANN-I-step | 0.6463 | — |
| TSANN-II |
| 0.6855 |
aAUC: area under the receiver operating curve.
bLR: logistic regression.
cMLP: multilayer perceptron.
dLSTM: long short-term memory.
eALSTM: attention long short-term memory.
fTLSTM: time-aware long short-term memory.
gATTAIN: Attention-based Time-aware Disease Progression.
hRETAIN: Reverse Time Attention model.
iTSANN: time-sensitive attentive neural network.
jThe optimal value for each column is italicized.
Figure 4An example of a heatmap with highly associated clinical variables, such as hypoxemia (D_799.02), shortness of breath (D_786.05), and wheezing (D_786.07).
Clinical variables with the top-ranked weights (/N stands for the clinical variable presented in N months before the prediction date).
| Sr. No. | ICDa-9/occurrence time | Medication/occurrence time |
| 1 | 493.9×asthma/0-5b (meaning diagnosed with asthma multiple times before exacerbation) | Methylprednisolone/0, 1c |
| 2 | 786.07 wheezing/0-2d | Prednisone/0, 1, 2c |
| 3 | 496.0 chronic airway obstruction not elsewhere classified/0, 1e | Ipratropium/0, 1, 2c |
| 4 | 530.81 esophageal reflux/0b | Midazolam/0, 1, 2d |
| 5 | V46.2 dependence on supplemental oxygen/0d | Hydromorphone/0-2e |
| 6 | 787.02 nausea alone/0d | Heparin/0, 1d |
| 7 | 786.50 unspecified chest pain/0d | Acetaminophen-oxycodone/0b |
| 8 | V08 HIV infection status/0e | Fentanyl/0e |
| 9 | 786.59 other chest pain/0d | Methylprednisolone/2-4e |
| 10 | 786.05 shortness of breath/0d | Glycopyrrolate/0b |
| 11 | V58.69 long-term (current) use of other medications/0e | Lidocaine/0d |
| 12 | 784.0 headache/0e | Dexamethasone/0d |
| 13 | 346.90 migraine, unspecified, without mention of intractable migraine without mention of status migrainosus/0e | Promethazine/0d |
| 14 | V58.66 long-term (current) use of aspirin/0b | Atorvastatin/0d |
| 15 | 491.21 obstructive chronic bronchitis with (acute) exacerbation/0e | Furosemide/0c |
aICD: International Classification of Disease Code.
bIdentified possible risk factors of asthma exacerbations by the domain expert. The authors regard these as containing valuable information.
cThese medications can be used to treat asthma or control the symptoms of asthma. In this study, it was difficult to determine whether these medications are risk factors as we were unable to investigate the dosage of these medications in the current study. Inappropriate medication use, short-acting beta agonists/inhaled corticosteroids, could also lead to asthma exacerbations.
dThese factors were symptoms, comorbidities, or combined medications. We believe they were not risk factors for asthma exacerbations.
eIt could hardly be determined whether these factors caused asthma exacerbations, but they demonstrated high associations. The authors regard these as containing valuable information.
Figure 5Time distribution of the contribution of the clinical variable gastroesophageal reflux disease is denoted by ICD-9:530.81. ICD: International Classification of Disease Code.
Figure 6The time distribution of the contribution of the clinical variable fentanyl.